Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Rituximab vs other disease‐modifying treatments

Interferon beta or glatiramer acetate · relapsing multiple sclerosis

Rituximab as 'first choice' probably leads to lower interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.14 [0.05, 0.39]
335 participants
Moderate